2020
Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol
Ghonem NS, Auclair AM, Hemme CL, Gallucci GM, de la Rosa Rodriguez R, Boyer JL, Assis DN. Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol. Clinical Pharmacology & Therapeutics 2020, 108: 1213-1223. PMID: 32480421, PMCID: PMC7886378, DOI: 10.1002/cpt.1930.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBile Acids and SaltsBiomarkersCholangitis, SclerosingCytokinesDrug Therapy, CombinationFemaleFenofibrateHumansInflammation MediatorsLiverLiver Cirrhosis, BiliaryLiver Function TestsMaleMiddle AgedPPAR alphaPrincipal Component AnalysisRetrospective StudiesTreatment OutcomeUrsodeoxycholic AcidYoung AdultConceptsPrimary sclerosing cholangitisPrimary biliary cholangitisBile acid metabolismSclerosing cholangitisBiliary cholangitisBile acidsAcid metabolismPeroxisome proliferator-activated receptor alphaProliferator-activated receptor alphaRetrospective observational studyBeneficial clinical effectsCholestatic liver diseasePro-inflammatory cytokinesBile acid metabolitesHealthy control subjectsBile acid poolSerum alkaline phosphataseAminotransferase abnormalitiesUrsodiol therapyFenofibrate therapyPartial respondersBile acid precursorsClinical effectsFenofibrate treatmentLiver disease
1997
Bile acid concentrations in human and rat liver tissue and in hepatocyte nuclei
Setchell K, Rodrigues C, Clerici C, Solinas A, Morelli A, Gartung C, Boyer J. Bile acid concentrations in human and rat liver tissue and in hepatocyte nuclei. Gastroenterology 1997, 112: 226-235. PMID: 8978363, DOI: 10.1016/s0016-5085(97)70239-7.Peer-Reviewed Original ResearchConceptsBile acid concentrationsBile acid administrationBile duct ligationBile acid poolLiver tissueBile acidsAcid administrationRat liver tissueDuct ligationTotal bile acid concentrationTissue concentrationsBile acid compositionSham-operated ratsLiver tissue levelsMajor bile acidsHydrophobic bile acidsHepatocyte nucleiAcid poolHuman liver tissueExperimental cholestasisAbstractTextTissue levelsRat hepatic nucleiAcid concentrationAdministration
1995
A randomized, double‐blind, placebo‐controlled trial of ursodeoxycholic acid in primary biliary cirrhosis
Combes B, Carithers R, Maddrey W, Lin D, McDonald M, Wheeler D, Eigenbrodt E, Muñoz S, Rubin R, Garcia‐Tsao G, Bonner G, West A, Boyer J, Luketic V, Shiffman M, Mills A, Peters M, White H, Zetterman R, Rossi S, Hofmann A, Markin R. A randomized, double‐blind, placebo‐controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995, 22: 759-766. PMID: 7657280, DOI: 10.1002/hep.1840220311.Peer-Reviewed Original ResearchConceptsPrimary biliary cirrhosisSerum bilirubinBiliary cirrhosisStratum 1Advanced primary biliary cirrhosisPlacebo-controlled trialBile acid poolLiver histologyPrognostic factorsTreatment failureSingle doseUrsodeoxycholic acidSevere symptomsPatientsUrsodiolLaboratory testsPlaceboHistologyBilirubinCirrhosisBiochemical testsGood responseStratum 3Acid poolLess effectA randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis
Combes B, Carithers R, Maddrey W, Lin D, Mcdonald M, Wheeler D, Eigenbrodt E, Muñoz S, Rubin R, Garcia-tsao G, Bonner G, West A, Boyer J, Luketic V, Shiffman M, Mills A, Peters M, White H, Zetterman R, Rossi S, Hofmann A, Markin R. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995, 22: 759-766. DOI: 10.1016/0270-9139(95)90294-5.Peer-Reviewed Original ResearchPrimary biliary cirrhosisSerum bilirubinBiliary cirrhosisMajor complicationsStratum 1Liver diseaseTreatment failureAdvanced primary biliary cirrhosisPlacebo-treated patientsPlacebo-controlled trialBile acid poolStratum 3Advanced diseaseLiver histologyPrognostic factorsMilder diseaseSingle doseUrsodeoxycholic acidUrsodiolSevere symptomsPatientsPlaceboLaboratory testsComplicationsBilirubin
1978
Stimulation of thymidine incorporation in mouse liver and biliary tract epithelium by lithocholate and deoxycholate
Bagheri S, Bolt M, Boyer J, Palmer R. Stimulation of thymidine incorporation in mouse liver and biliary tract epithelium by lithocholate and deoxycholate. Gastroenterology 1978, 74: 188-192. PMID: 620891, DOI: 10.1016/0016-5085(78)90793-x.Peer-Reviewed Original ResearchConceptsCertain bile acidsBiliary tractBile acidsBiliary tract epitheliumSingle oral dosesBile duct hyperplasiaBile acid poolBile saltsDuctular cell hyperplasiaPeliosis hepatisOral dosesHepatocellular necrosisBile ductCell hyperplasiaDuct hyperplasiaEnterohepatic circulationHepatic nodulesProliferative activityThymidine incorporationLiverEarly effectsLithocholateMouse liverDosesCell kinetics
1974
Variation in hepatic bile composition following cholecystectomy in patients with previous gallstones.
Boyer J, Bloomer J, Maddrey W, Tilson D. Variation in hepatic bile composition following cholecystectomy in patients with previous gallstones. The Yale Journal Of Biology And Medicine 1974, 47: 211-7. PMID: 4456833, PMCID: PMC2595121.Peer-Reviewed Original ResearchConceptsHepatic bileBile compositionEnterohepatic circulationBile acidsBile acid poolLithogenicity of bileHepatic bile compositionBile specimensDay study periodT-tubeCholesterol gallstonesPatientsExcretion rateCholecystectomyBileStudy periodGallstonesAcid poolAdmirandGallbladderLithogenicityCirculation